Participated · Seed · Oct 2025

Founded in 2021 by Hannah Samano, Unfabled uses a community-driven R&D approach called Unfabled Labs to identify and validate women’s health needs before launching products. Its Essentials supplement line targets issues such as bloating, cramps, low energy, sleep problems, and stress, and has quickly expanded from an initial 50 Boots stores to 737 locations—a more than 1,000% retail footprint increase. The company combines data insights, scientific backing, and lived experience to create products "by women, for women." Direct-to-consumer traction has translated into retail momentum, earning Unfabled a place in Boots’ Ignite accelerator for trending brands. To date, the startup has secured just over €3.3 million in seed funding, 67% of which comes from female investors, reflecting its mission to improve gender representation in both healthcare and venture capital. Unfabled positions itself as a leading voice in the growing European femtech sector, aiming to build a broader category of accessible, consumer-focused women’s health solutions.

Participated · Series A · Apr 2025

CSignum develops patented EM-2 systems that use electromagnetic field signaling (EMFS) to wirelessly transmit data through challenging environments such as water, ice, soil, rock and concrete to surface networks. Its core offerings include EM-2 hardware and CSignum Cloud, a dashboard and analytics platform already deployed on several river water quality monitoring projects. Key applications include water quality and environmental monitoring, wireless under-ship monitoring, and security for critical underwater infrastructure such as offshore wind turbines and oil and gas platforms. Founded in 2020, the company is working with customers in the UK, EU and US to address regulatory-driven demand for real-time monitoring. Upcoming compliance deadlines, including AMP8 real-time monitoring mandates, present a significant growth opportunity for its wireless solutions. The company plans to use the funding to expand its engineering team, advance its product portfolio and strengthen its market presence.

Led · Equity · Nov 2024

Biotangents has developed a cost‑effective on‑farm molecular diagnostic that returns highly accurate results in less than two hours, enabling informed treatment decisions for dairy farmers. The device sends data to the farmer’s phone and can integrate with farm management systems, vets, and milk processors. The technology is aimed at reducing unnecessary antibiotic use (estimated unnecessary treatment in up to 40% of cases) and addressing antimicrobial resistance while improving herd health, productivity, and sustainability. Biotangents is focused on next‑generation diagnostics for the animal health sector, with potential future applications in human healthcare and environmental monitoring. The company announced a £2.3m investment round to support development and commercialisation and will commence on‑farm trials across the UK and internationally next year. Biotangents was founded in 2015 as a University of Edinburgh spinout and is headquartered at the Pentlands Science Park near Edinburgh. Biotangents, founded in 2015, is based at the Pentlands Science Park just outside Edinburgh. The company has developed Isothermal technology for rapid detection of a range of animal diseases including Bovine Viral Diarrhoea (BVD) and Mastitis. Its AmpliSpec™ Mastitis diagnostic test cuts detection time from several days to just a few hours. Leadership includes founders Dr Andy Hall-Ponselè and Lina Gasiūnaitė, with Fiona Marshall as CEO, Ian Hamilton as Chairman and Ross McDermid as Director of Commercialisation. Biotangents intends to use the new funds to develop and roll out its on-farm rapid disease detection technology. Financially, the company has raised prior rounds of £1.2m in August 2021 (led by Kelvin Capital) and £1.5m in May 2019.

Participated · Equity · Nov 2023

1nhaler, headquartered in Edinburgh, is building a novel pop-up dry-powder inhaler (DPI) made predominantly from eco-friendly cardboard. The single-dose, disposable device folds from a credit-card shape into a three-dimensional inhaler through a patent-protected membrane system, tackling the cost, usability, and environmental drawbacks of traditional plastic inhalers. Performance data from its lead product matches leading multidose DPIs, and the platform can be tuned to deliver a range of dry-powder drugs for conditions such as asthma, COPD, influenza, and Parkinson’s. Recent funding will support the manufacture of clinical material, development of large-scale production processes, and preparation of a first Marketing Authorisation Application targeted for late 2027. The company has secured manufacturing partnerships with Upperton for clinical supply and Harro Höfliger for commercial scale-up. Founders Don Smith and Lisa McMyn have assembled an experienced leadership team, including former GSK and AstraZeneca executives, to steer the product toward commercialisation. 1nhaler is actively engaging potential pharmaceutical partners to bring both new and existing inhalable therapies to market more sustainably and cost-effectively.

Participated · Equity · May 2021

Algbra operates a financial-management app that emphasizes ethical and sharia-compliant investing, including tracking the carbon footprint of every transaction to raise user awareness. The platform actively advises users against "unethical or high-risk" investments and offers ESG-centric B2B solutions. Algbra is B Corporation certified and is the first sharia-compliant fintech authorised by the Financial Conduct Authority as an Electronic Money Institution. The company has entered a strategic tie-up with SC Ventures and its Shoal sustainable finance platform, and SC Ventures has bought a stake in Algbra (terms undisclosed). Shoal will leverage Algbra’s technology to distribute products to UK retail customers, while Algbra plans to incorporate Shoal into its global ESG B2B offerings. Founders Zeiad Idris and Fizel Nejabat say the company intends to expand beyond the UK to serve communities in Asia, Africa and the Middle East. Algbra is a sustainable, values-focused digital finance provider founded by CEO Zeiad Idris and COO Fizel Nejabat that targets financially overlooked minority communities. The platform is built around principles of transparency, fairness, sustainability and non-interest based finance to serve ethically-minded consumers. The firm plans to launch core financial products including current accounts, foreign exchange, remittances and rewards, with lending products to follow shortly thereafter. Algbra positions itself to serve a global market that includes 2 billion Muslims (about 800 million of whom are unbanked) and aims to facilitate social mobility and financial inclusion. The company has recruited an advisory board featuring former executives such as Nicolas Huss, Shabir Randeree CBE and others to support its mission. Financially, Algbra has raised £3.75m in fundraising to support product launch and growth, backed by SFC Capital, British Business Investments and New World Group.